Table 2.
Summary of antimultiple myeloma compounds based on selected patents.
| Number | Patent | Multiple myeloma agents (targets) | Assignee | Year | Ref. |
|---|---|---|---|---|---|
| P-1 | WO061199A1 | Staurosporine derivatives (FGFR3/c-fos/Ras) | Novartis Pharma Gmbh | 2006 | [47] |
| P-2 | WO060676A1 | NPI-0052 (Salinosporamide A) (proteasome) | Dana-Farber Cancer Institute | 2006 | [48] |
| P-3 | WO118953A2 | 17-allylamino- 17-demethoxy-geldanamycin (17-AGG) or 17-amino geldanamycin (17-AG) (Hsp90) | Kosan Biosciences, Inc. | 2006 | [49] |
| P-4 | WO116185A2 | MDX-1338 (CXCR4) | CBR institute for biomedical research, Inc | 2006 | [50] |
| P-5 | US079461A1 | P38 inhibitor (MAPK) | Scios, Inc. | 2006 | [51] |
| P-6 | WO026251A2 | 2-aminoarylthiazoles 2-aminoaryloxazoles (c-Kit/ FGFR3) |
AB SCI- ENCE | 2007 | [52] |
| P-7 | WO059078A1 | Dasatinib (multi-kinase) | Dana-Farber Cancer Institute | 2007 | [53] |
| P-8 | EP-1443927-B1 | Carboline derivatives (NF-κB) | Millennium pharmaceuticals, Inc. | 2007 | [54] |
| P-9 | US7196105 | Curcumin (NF-κB) | Research Development Foundation | 2007 | [55] |
| P-10 | US7211252 | Antagonists for Alpha4 intergrin binding agents (VCAM-1, VLA-4) | University of Texas System | 2007 | [56] |
| P-11 | WO002553 A1 | Erastin analogues (Ras) | Prolexys Pharmaceuticals, Inc. | 2009 | [57] |
| P-12 | WO034414A1 | 2,3-dihydroimidazo[1,2-c] quinazoline (PI3K/Akt) | Bayer Schering PharmaAktiengesellschaft | 2010 | [58] |
| P-13 | WO138141A1 | [(lR)-I-[[(2S,3R)-3-hydroxy-2-[6-phenyl-pyridine-2- carbonyl)amino]-1-oxobutyl]amino]-3-methylbutylboronic acid (proteasome) | Cephalon, Inc. | 2010 | [59] |
| P-14 | EP-1684805-B1 | CHIR-12.12, CHIR-5.9 (CD40 monoclonal antibodies) | Novartis Vaccines and Diagnostics Inc. | 2010 | [60] |
| P-15 | US7968569 | 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dion (TNF- α) | Celgene Corporation | 2011 | [45] |
| P-16 | US8012477 | IL-17 binding molecule (IL-17) | Novartis AG and Novartis Pharma GmbH | 2011 | [61] |
| P-17 | US8268807 | (E)-3-hydroxy-21-[2'-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene (IL-6) | SRI International | 2012 | [62] |
| P-18 | WO136732 A1 | Masitinib (c-Kit/ FGFR3/ PDGFR) | AB SCI- ENCE | 2012 | [63] |
| P-19 | WO134915A1 | Ezatiostat (GSTP1-1) | Telik, Inc. | 2012 | [64] |
| P-20 | WO149602A1 | N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide (CYT387) (JAK) | YM BioSciences Australia Pty Ltd | 2012 | [65] |
| P-21 | WO022919A1 | 2-((3,4-bis(benzyloxy)benzyl)amino) ethan-1-ol (XRK3) (p62) | Xie, X-Q., et al. University of Pittsburgh | 2013 | [66] |
| P-22 | US0040979 | CCR1 antagonists (CCR1) | Millennium Pharmaceuticals,Inc | 2013 | [67] |
| P-23 | US0172388A1 | phenylacetylamide (PAM) (CB2) | Xie, X-Q., et al. University of Pittsburgh | 2013 | [68] |